GLOBUS MEDICAL INC - A (NYSE:GMED) emerged from a Decent Value screen, a methodology that filters for stocks with compelling valuation ratios while still maintaining acceptable levels of profitability, financial health, and growth. For value investors, this balanced approach helps avoid the classic value trap where cheapness masks deteriorating fundamentals, making the screen a practical starting point for identifying potentially undervalued opportunities.
Why GMED Fits the Decent Value Profile
The Decent Value screen requires a strong fundamental valuation score, and GMED delivers on that front. Its trailing Price/Earnings ratio of 18.34 is cheaper than 84% of its Health Care Equipment & Supplies peers, and the forward P/E of 15.51 also sits well below the industry median. More importantly, the Enterprise Value to EBITDA and Price to Free Cash Flow multiples both rank among the cheapest quartile in the sector, signaling that the market may be discounting the company’s earning power despite its solid operations. Investors who want to examine the full set of valuation metrics against the backdrop of profitability and growth can consult the detailed fundamental analysis report.
What makes GMED stand out is that its low valuation does not come at the expense of quality. The ChartMill ratings tell a consistent story:
- Valuation rating: 7/10 — cheap versus industry on P/E, EV/EBITDA, and P/FCF; PEG ratio also supports a reasonable price relative to expected growth.
- Profitability rating: 8/10 — Return on Assets (10.79%), Return on Equity (12.40%), and Return on Invested Capital (10.57%) all outperform at least 86% of industry peers. Profit and operating margins are similarly strong and have been trending higher.
- Health rating: 8/10 — an Altman-Z score of 11.08 indicates negligible bankruptcy risk. Debt is effectively zero (Debt-to-FCF ratio of 0.00), and the current ratio of 4.56 confirms ample liquidity.
- Growth rating: 8/10 — EPS grew 43% over the past year and has compounded at nearly 23% annually over longer periods. Revenue growth of 23% last year is also robust, though forward estimates moderate to around 8–13% annually.
These attributes are exactly what a value investor looks for: a company whose market price implies pessimism, yet whose underlying business demonstrates consistent profitability, strong financial health, and a track record of expansion.
Balancing Value with Quality
The combination of a high valuation score and top-quartile profitability and health ratings means GMED offers a margin of safety — a core tenet of value investing originally articulated by Benjamin Graham. The low debt load and strong cash flow ensure the company can weather downturns, while the improving profit margins and ROIC above its trailing three-year average suggest that operational efficiency is on the rise. Although the growth rate is expected to decelerate from its recent blistering pace, the forward EPS growth of 13–14% still justifies a P/E in the mid-teens and positions GMED as a reasonably priced growth-at-a-reasonable-price candidate within the value framework.
For investors who seek stocks that are undervalued relative to their fundamentals without sacrificing quality, GMED represents a textbook example of what the Decent Value screen aims to surface. To explore a broader list of stocks that match this methodology — balancing valuation, profitability, health, and growth — visit the Decent Value Stocks screen.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Globus Medical (GMED) Emerges as a Decent Value Stock with Strong Fundamentals
GLOBUS MEDICAL INC - A (NYSE:GMED) emerged from a Decent Value screen, a methodology that filters for stocks with compelling valuation ratios while still maintaining acceptable levels of profitability, financial health, and growth. For value investors, this balanced approach helps avoid the classic value trap where cheapness masks deteriorating fundamentals, making the screen a practical starting point for identifying potentially undervalued opportunities.
Why GMED Fits the Decent Value Profile
The Decent Value screen requires a strong fundamental valuation score, and GMED delivers on that front. Its trailing Price/Earnings ratio of 18.34 is cheaper than 84% of its Health Care Equipment & Supplies peers, and the forward P/E of 15.51 also sits well below the industry median. More importantly, the Enterprise Value to EBITDA and Price to Free Cash Flow multiples both rank among the cheapest quartile in the sector, signaling that the market may be discounting the company’s earning power despite its solid operations. Investors who want to examine the full set of valuation metrics against the backdrop of profitability and growth can consult the detailed fundamental analysis report.
What makes GMED stand out is that its low valuation does not come at the expense of quality. The ChartMill ratings tell a consistent story:
These attributes are exactly what a value investor looks for: a company whose market price implies pessimism, yet whose underlying business demonstrates consistent profitability, strong financial health, and a track record of expansion.
Balancing Value with Quality
The combination of a high valuation score and top-quartile profitability and health ratings means GMED offers a margin of safety — a core tenet of value investing originally articulated by Benjamin Graham. The low debt load and strong cash flow ensure the company can weather downturns, while the improving profit margins and ROIC above its trailing three-year average suggest that operational efficiency is on the rise. Although the growth rate is expected to decelerate from its recent blistering pace, the forward EPS growth of 13–14% still justifies a P/E in the mid-teens and positions GMED as a reasonably priced growth-at-a-reasonable-price candidate within the value framework.
For investors who seek stocks that are undervalued relative to their fundamentals without sacrificing quality, GMED represents a textbook example of what the Decent Value screen aims to surface. To explore a broader list of stocks that match this methodology — balancing valuation, profitability, health, and growth — visit the Decent Value Stocks screen.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »